1. Lorne Cancer Conference – Student Travel Bursaries
The Lorne Cancer Conference Committee invites applications for its travel bursaries. These support Australian students in attending the Lorne Cancer Conference, to be held in Cumberland from 14 to 16 February 2019.
Candidates must submit an abstract for the conference.
Bursaries are intended to assist with interstate travel costs.
Closing date 02 Nov 18
2. Physical activity and weight control interventions among cancer survivors – effects on biomarkers of prognosis and survival (R21 clinical trial optional; R01 clinical trial optional)
NIH: National Cancer Institute, US
This supports transdisciplinary and translational research that will identify the specific biological or biobehavioural pathways through which physical activity or weight control may affect cancer prognosis and survival.
There are two grant schemes here – R21 supports developmental/exploratory ideas; R01 is a larger grant. They have different closing dates (October), period of funding and funding amounts.
3. Advancing translational and clinical probiotic/prebiotic and human microbiome research (R01 clinical trial optional)
NIH/NCI and other funders
This supports translational and clinical studies using a variety of probiotic and prebiotic carriers to generate measurable functional evidence for the safe and effective use of these carriers in maintaining health or preventing and treating diseases, as well as studies to develop new or refine known biomarkers of health and disease with respect to probiotic or prebiotic interventions. This FOA calls for interdisciplinary collaborations across scientific disciplines engaged in microbiome and probiotic or prebiotic research that address the following topics: nutritional science; microbiology; virology; microecology and microbiome; genomics; immunology; computational biology; chemistry; bioengineering; integration of omics; computational approaches in DNA technologies. Where needed, it is mandatory that the applicant proposing clinical studies provides sufficient details of plans and appropriately documented evidence of pre-investigational new drug status and other relevant regulatory correspondence.
Deadline information Applications open on 5 September 2018 and are due by 5pm local time of applicant organisation every 5 October, 5 February and 5 June until 8 September 2021.
4. Modular R01s in cancer control and population sciences (R01 clinical trial optional)
NIH: National Cancer Institute, US and other funders
This supports research in cancer control and population sciences as part of NCI’s Division of Cancer Control and Population Sciences’ mission to reduce risk, incidence and deaths from cancer, as well as to enhance the quality of life for cancer survivors.
The aim is to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviours and behavioural interventions, health care delivery and implementation science. Applications addressing a variety of these topics are encouraged.
Grants are worth up to USD 250,000 each per year over a maximum period of five years.
Maximum award: USD 1,250,000
Closing date: 07 Nov 18 (recurring)